Poitras v. GLAXO SMITHKLINE CONSUMER HEALTHCARE

635 F. Supp. 2d 1003, 2009 U.S. Dist. LEXIS 54990, 2009 WL 1850902
CourtDistrict Court, E.D. Missouri
DecidedJune 29, 2009
Docket4:07CV1736-DJS
StatusPublished

This text of 635 F. Supp. 2d 1003 (Poitras v. GLAXO SMITHKLINE CONSUMER HEALTHCARE) is published on Counsel Stack Legal Research, covering District Court, E.D. Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Poitras v. GLAXO SMITHKLINE CONSUMER HEALTHCARE, 635 F. Supp. 2d 1003, 2009 U.S. Dist. LEXIS 54990, 2009 WL 1850902 (E.D. Mo. 2009).

Opinion

635 F.Supp.2d 1003 (2009)

Susan E. POITRAS, Plaintiff,
v.
GLAXO SMITHKLINE CONSUMER HEALTHCARE, LP, Defendant.

No. 4:07CV1736-DJS.

United States District Court, E.D. Missouri, Eastern Division.

June 29, 2009.

*1006 William E. Moench, William E. Moench Law Offices, St. Louis, MO, for Plaintiff.

Carrie A. McAtee, Shook Hardy, L.L.P., Kansas City, MO, for Defendant.

ORDER

DONALD J. STOHR, District Judge.

Now before the Court is defendant Glaxo SmithKline Consumer Healthcare's motion for summary judgment [Doc. #14], and plaintiff Susan E. Poitras' opposition thereto. The matter has been fully briefed and is ready for disposition.

Standard of Review

In considering a motion for summary judgment, the Court must "view all of the evidence in the light most favorable to the nonmoving party and [will] give that party the benefit of all reasonable inferences to be drawn from the facts disclosed in the pleadings." Reich v. ConAgra, Inc., 987 F.2d 1357, 1359 (8th Cir.1993). "Summary judgment is appropriate if there is no genuine issue of material fact and the moving party is entitled to judgment as a matter of law." Id. "Although the moving party has the burden of demonstrating the absence of genuine issues of material fact, the `nonmoving party may not rest upon mere denials or allegations, but must instead set forth specific facts sufficient to raise a genuine issue for trial.'" Burchett v. Target Corp., 340 F.3d 510, 516 (8th Cir.2003) (quoting Rose-Maston v. NME Hosps., Inc., 133 F.3d 1104, 1107 (8th Cir. 1998)). "To overcome a motion for summary judgment, `[a] plaintiff may not *1007 merely point to unsupported self-serving allegations, but must substantiate allegations with sufficient probative evidence that would permit a finding in the plaintiff's favor.'" Reed v. Lear Corp., 556 F.3d 674, 678 (8th Cir.2009) (quoting Davidson & Assocs. v. Jung, 422 F.3d 630, 638 (8th Cir.2005)).

Facts

For purposes of this motion, the Court finds that the following facts are not in dispute, or have not been properly controverted pursuant to E.D.Mo. L.R. 7-4.01(E).[1] The following facts are those established by the depositions, affidavits, and records submitted by the parties, and are viewed in the light most favorable to plaintiff.

Plaintiff started working for defendant in 1999 at defendant's St. Louis manufacturing facility, which produces Tums and Oscal tablets. Throughout her employment, plaintiff was a manufacturing technician. Defendant's manufacturing department is divided into four areas, each of which performs a specific function of the manufacturing process. These areas are "Blending," "Wet-Mix," "Tableting," and "Weigh-Up." For several years, plaintiff worked primarily in Tableting making Tums, although she was also trained in Blending and Weigh-Up and would work in those areas as needed. In approximately 2004, plaintiff began working primarily in Tableting making Oscal, although she continued to work in Blending, Weigh-Up, and other areas within Tableting as needed.[2]

Plaintiff worked the evening shift from sometime in 2001 or 2002 until the end of her employment. As a manufacturing technician on the evening shift, plaintiff reported to an evening shift unit leader, who in turn reported to the evening shift team leader. Plaintiff had various team leaders during her employment with defendant, including Randy Batson, Will Daugherty, and David Vinlove. Unit leader Bill Prott supervised plaintiff in Tableting, and unit leader Pete Petruso supervised plaintiff in Blending and Weigh-Up.

Defendant has published Standard Operating Procedures ("SOPs"). The SOPs, among other things, give basic instruction on how to operate the machinery and how to handle a document that is involved in that operation. Defendant has a specific SOP that establishes the procedure for lot number identification of raw materials. Pursuant to this SOP, an employee is responsible for verifying that the approved lot of raw material was being used by following this four-step procedure:

A. Upon receipt, each pallet of raw material will be marked with its GSK #, and receiving date; these appear on the pallet ticket.
B. Each new pallet of material and each bag MUST be checked by the Operator for the proper lot number before using.
C. Operators should check the receiving dates and GSK # as closely as the lot number as these play an essential role in identifying the lot and in inventory.
D. If during the check, an odd lot number is found, STOP PRODUCTION and notify the Manufacturing Team Leader and Quality Department.

Of note, performing step (B) of this procedure checks that employees know what material is approved for use. Although *1008 plaintiff was trained on some SOPs, plaintiff states she cannot recall if she was specifically trained on the above SOP.

When working in Weigh-Up, plaintiff regularly used a mix sheet that set out steps and procedures for weighing the raw ingredients for tablet mixes. Similar to the SOP, the procedure on the mix sheet requires operators to obtain an approved lot and verify that they are using raw material that has been approved by visually checking the appropriate information. Operators must verify that they have completed this step of the required procedure by signing off on each mix sheet.

Plaintiff's work was also regulated by the Federal Drug Administration ("FDA"). Among other things, FDA regulations require defendant to keep track of and document which lot number of raw material goes into which batch. Plaintiff agrees that complying with all quality FDA and safety regulations, following SOPs, and completing batch record documentation correctly the first time were key responsibilities of her job. Plaintiff understood defendant's expectation that she record descriptions of all of her work in the manner directed by the company.

Defendant employs a progressive discipline system. Under this policy, the progressive disciplinary steps are: i) verbal warning; ii) written warning; iii) demotion; and iv) separation. Depending on the situation, an employee may receive a Performance Improvement Plan ("PIP") along with a written warning. The employee's performance is reviewed with the employee periodically during the term of the PIP. An employee is removed from a PIP once she has successfully completed the term of the PIP with no performance issues.

Defendant states that even if an employee is removed from a PIP, the employee is still considered to be at that step of the progressive discipline process. Further, defendant states that if an employee has additional performance problems after having been on a PIP, the employee is subject to an extended written warning or termination of employment, depending on the seriousness of the additional performance problems.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Barbara McLaughlin v. Esselte Pendaflex Corporation
50 F.3d 507 (Eighth Circuit, 1995)
Smith v. Allen Health Systems
302 F.3d 827 (Eighth Circuit, 2002)
Clarence Putman v. Unity Health System
348 F.3d 732 (Eighth Circuit, 2003)
Selena Marquez v. Bridgestone/firestone, Inc.
353 F.3d 1037 (Eighth Circuit, 2004)
Davidson & Associates v. Jung
422 F.3d 630 (First Circuit, 2005)
Reeves v. Sanderson Plumbing Products, Inc.
530 U.S. 133 (Supreme Court, 2000)
Phillips v. Mathews
547 F.3d 905 (Eighth Circuit, 2008)
Reed v. Lear Corp.
556 F.3d 674 (Eighth Circuit, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
635 F. Supp. 2d 1003, 2009 U.S. Dist. LEXIS 54990, 2009 WL 1850902, Counsel Stack Legal Research, https://law.counselstack.com/opinion/poitras-v-glaxo-smithkline-consumer-healthcare-moed-2009.